Beyond mRNA - how advances in analytical techniques are enabling a revolution of the RNA drug landscape

Currently, there are three main types of in vitro transcribed (IVT) RNA drugs: conventional, non-replicating mRNA; base-modified, non-replicating mRNA (bmRNA), which incorporate chemically modified nucleotides; and self-replicating RNA (srRNA), based on an engineered viral genome but devoid of viral structural protein genes.

The ability to create copies of the drug after administration enables lower dosing and expands the range of potential indications. However, srRNAs are often much larger in size (9,000-16,000 bases) and traditional biophysical analytical techniques, such as capillary electrophoresis (CE), have been challenging to adapt to these large molecules.

This presentation will showcase how to achieve improved characterization of srRNA using the newest advances in CE. Additionally, we will discuss how these complement and augment in vitro cell-based assays currently being used for potency testing.

• Learn about the potential of srRNA as a vaccine and therapeutic modality
• Explore how advances in CE can overcome analytical difficulties when assessing RNA up to 16,000 bases
• Hear about how cell-based potency assays correlate with purity and size assessment with capillary gel electrophoresis

Andrew Geall

Chief Development Officer and Co-Founder at Replicate Bioscience

Dr Andrew Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of in vitro transcribed (IVT) RNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.

Prior to joining Replicate, Andrew held multiple leading positions at Novartis, Avidity Biosciences and Precision NanoSystems Inc. (PNI) focusing on mRNA vaccines, siRNA, formulation, antibody-oligonucleotide conjugate delivery and nanoparticle drugs. In addition, he was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-replicating RNA vaccines.

Andrew received his pharmacy degree from the University of Bath in the UK and obtained his PhD at the University of Bath in non-viral gene delivery.

Watch now

SPEAKERS

Andrew Geall

Chief Development Officer and Co-Founder at Replicate Bioscience

You might also like

Faster, smaller, smarter: intelligent manufacturing of mRNA through the power of process analytical technologies

Aaron Cowley, Edita Botonjic-Sehic

11 December

Watch

Enhancing mRNA production with advanced analytics: WACKER Biotech

Michael Daume, Blaz Bakalar

8 October

Watch

Unlocking mRNA-LNP potential using a novel lipid library combined with innovative analytical methods

Nejc Pavlin, Guillaume Freund

11 September

Watch

Optimized and scalable LNP composition for RNA vaccine delivery

Martin Rabel

25 September

Watch

Scalable chromatographic strategies for mRNA and saRNA purification from IVT

Tomas Kostelec

29 February

Watch